Treatment of Nontuberculous Mycobacterial Infections (NTM)
|
|
- Herbert Benson
- 6 years ago
- Views:
Transcription
1 Treatment of Nontuberculous Mycobacterial Infections (NTM) Charles L. Daley, MD National Jewish Health University of Colorado, Denver
2 Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory Committee Insmed (inhaled liposomal amikacin) Johnson and Johnson (bedaquiline) Data Monitoring Committee Novartis (clofazimine)
3 NTM That Have Been Reported to Cause Lung Disease Slowly Growing Mycobacteria Rapidly Growing Mycobacteria* M. arupense M. kubicae M. abscessus M. holsaticum M asiaticum M. lentiflavum M. alvei M. fortuitum M. avium M. malmoense M. boenickei M. mageritense M. branderi M. palustre M. bolletii M. massiliense M. celatum M. saskatchewanse M. brumae M. mucogenicum M. chimaera M. scrofulaceum M. chelonae M. peregrinum M. florentinum M. shimodei M. confluentis M. phocaicum M. heckeshornense M. simiae M. elephantis M. septicum M. intermedium M. szulgai M. goodii M. thermoresistible M. interjectum M. terrae M. intracellulare M. triplex M. kansasii M. xenopi * Growth in subculture within 7 days
4 NTM That Have Been Reported to Cause Lung Disease Slowly Growing Mycobacteria Rapidly Growing Mycobacteria* M. arupense M. kubicae M. abscessus M. holsaticum M asiaticum M. lentiflavum M. alvei M. fortuitum M. avium M. malmoense M. boenickei M. mageritense M. branderi M. palustre M. bolletii M. massiliense M. celatum M. saskatchewanse M. brumae M. mucogenicum M. chimaera M. scrofulaceum M. chelonae M. peregrinum M. florentinum M. shimodei M. confluentis M. phocaicum M. heckeshornense M. simiae M. elephantis M. septicum M. intermedium M. szulgai M. goodii M. thermoresistible M. interjectum M. terrae M. intracellulare M. triplex M. kansasii M. xenopi * Growth in subculture within 7 days
5 ATS Diagnostic Criteria For NTM Lung Disease Clinical Radiographs Bacteriology Cough Fatigue Weight Loss 2 positive sputum cultures ATS/IDSA AJRCCM 2007;175:367
6 Correlation of Cultures and Progression 14% with 1 positive sputum culture for MAC progressed over median of 16 mos 1 38% with CF/MAC with 1 positive sputum cultures progressed over median of 4.4 yrs 2 98% with 2 positive sputum cultures for MAC progressed over at least 12 mos follow-up 3 1 Koh WJ, et al. Diagn Microbiol Infect Dis Martiniano S, et al. Ann Am Thorac Soc Tsukamura M. Chest 1991;99:667
7 Treatment of NTM Background No treatments are approved for treatment of NTM lung infections. Treatment requires multidrug regimens given for long treatment durations (>12 mos). Treatment vary by species, is of long duration, and often associated with drug-related toxicity. Treatment outcomes vary by species and are associated with high rates of recurrence and reinfection. Griffith DE, et al. Curr Opin Infect Dis. 2012;25(2):
8 Drugs Used for the Treatment of NTM Oral Parenteral Inhaled Macrolides (azithromycin, clarithromycin) Rifamycins (rifampin, rifabutin) Ethambutol Isoniazid Fluoroquinolones (moxifloxacin, ciprofloxacin) Cyclines (doxycycline, minocycline) Sulfonamides Oxazolidinones (linezolid, tedizolid) Clofazimine Aminoglycosides (streptomycin, amikacin) Carbapenems (imipenem, meropenem) Cefoxitin Tigecycline Aminoglycosides (amikacin)
9 NTM Pulmonary Infections Whom to Treat? Under diagnosis Disease progression Over diagnosis Drug toxicity
10 NTM Pulmonary Infections Whom to Treat? Increased susceptibility? Clinical symptoms and overall condition of patient Extent of radiograph abnormalities and whether there is evidence of progression Species that has been isolated Bacteriologic load (smear + vs. smear -) Cure, bacteriologic conversion, relief of symptoms, prevention of progression
11 NTM Treatment Regimens Goals NTM Drugs Duration Expected Cure M. kansasii Isoniazid (macrolide) >12 mo 95% Ethambutol Rifamycin MAC* Macrolide (azithromycin) >12 mo 56% to 85% Ethambutol Depends on extent of disease Rifamycin M. abscessus Macrolide (azithromycin) >12 mo 25-80% Cefoxitin or imipenem (IV) Depends on subspecies Amikacin (IV or inhaled) Other oral drugs? *Three times weekly for nodular bronchiectatic MAC without cavitation Note: aminoglycoside for cavitary disease ATS/IDSA AJRCCM 2007
12 Case 35 year old Caucasian woman from Florida with cough for several weeks
13 Mycobacterium avium Complex MAC Tortoli E. Clin Micro Rev 2014;27:
14 Treatment of Pulmonary M. avium complex Yes Cavities Present No 3X/WEEK Azithromycin Rifampin Ethambutol Yes DAILY Azithromycin Rifampin Ethambutol MAC Macrolide sensitive Clofazimine Moxifloxacin Ciprofloxacin Bedaquiline Inh. amikacin Other drugs? Add IV Amikacin No DAILY Rifampin Ethambutol Other drug Duration :12 mos culture negativity
15 Treatment Outcomes for MAC Macrolide susceptible Non cavitary Cavitary Macrolide resistant No surgery/aminoglycoside Some surgery/aminoglycoside Surgery + prolonged aminoglycoside* * 6 months IV aminoglycoside Culture Conversion 80% <80% 5% 15% 80% Griffith DE, et al. AJRCCM 2006;174:928 Wallace R, et al. Chest 2014:146: Jeong BH, et al. AJRCCM 2015:191: Moon SM, et al. Antimicrob Agents Chemother 2016, epub
16 Measure Microbiologic recurrence after sputum conversion MAC Recurrences Relapse vs reinfection University of Texas, Tyler 1 After Completion of Therapy (n=155) Northwestern 2 After Completion of Therapy (n=190) 48% 25% New infection* 75% 46% True Relapse 25% 54% * Determined by pulse field electrophoresis 1. Wallace R, et al. Chest 2014;146: Boyle DP, et al. Ann Am Thorac Soc 2016 (epub)
17 Strengthen the Treatment Regimen Regimen Intermittent to Daily Dosing 30% culture conversion Repurposed Drugs (moxifloxacin, amikacin, clofazimine) 30% culture conversion New Drugs (bedaquiline, delamanid)
18 M. avium complex Summary MAC pulmonary disease should be treated with a macrolide-based regimen An aminoglycoside should be considered in cavitary disease and when macrolide resistance is present The optimal duration of therapy is not know but should be at least 12 months beyond the point of culture conversion Surgery may increase bacteriologic conversion, particularly in presence of macrolide resistant
19 Case 68 year old woman with chronic cough and fatigue
20 Mycobacterium abscessus Mycobacterium abscessus was first identified in a patient with a knee infection and SQ abscesses M. abscessus is the second or third most common cause of lung disease due to NTM and the most common cause of lung disease due to a rapid grower The organism is highly resistant to antibiotics with current in vitro methods Isolated in 1950 from synovial fluid and buttock lesions in a 63 year old woman Moore M et al. J Invest Derm. 1953;20:133
21 Evolving Taxonomy Functional erm(41) gene 80% 0% 100%? Griffith D, et al. Ann Am Thorac Soc 2015;12:436 Cho YJ, et al. PLoS ONE (11):e81560 Tortoli E, et al. Int J Syst Evol Microbiol 2016;epub
22 Yes Macrolide? 2 other drugs Amikacin M. abscessus Functional erm41 gene No Macrolide 1 other drug Amikacin 2+ mos Imipenem (IV) Cefoxitin (IV) Tigecycline (IV) Linezolid Clofazimine Moxifloxacin Bedaquiline New drug? 2+ mos Macrolide? 2 other drugs Inhaled Amikacin Treatment of M. abscessus complex M. abscessus M. bolletii Duration 12 mos culture negativity M. massiliense Macrolide 1 other drug Inhaled Amikacin
23 Treatment Outcomes for Pulmonary M. abscessus vs. M. massiliense Study Population Subspecies N Sputum conversion Koh, 2011 Lyu, 2014 Roux, 2015 Non Cystic Fibrosis Non Cystic Fibrosis Cystic Fibrosis M. abscessus M. massiliense M. abscessus M. massiliense M. abscessus M. massiliense % 88% 42% 96% 25% 86% Failure to convert 58% 3% 27% 0% - - Relapse 17% 9% 31% 5% - - Koh WJ, et al. Am J Respir Crit Care Med 2011;183:405-10
24 M. abscessus Summary M. abscessus has high levels of in vitro resistance to many antibiotics Treatment requires a combination of intravenous, oral, and inhaled antibiotics Presence of an erm (41) gene appears to impact treatment outcomes which are usually poor when a functional erm gene is present. Surgical resection may increase bacteriologic conversion
25 Thank You! The Maroon Bells, Aspen, Colorado
Treatment of Slowly Growing NTM Infections
Treatment of Slowly Growing NTM Infections Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory Committee Insmed
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationNon-Tuberculous Mycobacterial Pulmonary Disease Diagnosis and Management Jakko van Ingen, MD, PhD
Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) 1 Radbound University Nihmegen Medical Center Milestones in NTM research 1980s: Nodular bronchiectatic lung disease Lady Windermere syndrome 1882-1890
More informationTing-Shu Wu, M.D. Infection Control Committee Infect Dis, Int Med, Chang Gung Memorial Hospital, Linkou Medical Center, Tao-Yuan, Taiwan
Ting-Shu Wu, M.D. Infection Control Committee Infect Dis, Int Med, Chang Gung Memorial Hospital, Linkou Medical Center, Tao-Yuan, Taiwan NTM Other than M. tuberculosis, M. africanum, M. bovis, M. caprae,
More informationDM seminar. Pulmonary diseases due to NTM & their management
DM seminar Pulmonary diseases due to NTM & their management Content 1. Introduction 2. Microbiology 3. Epidemiology 4. Diseases 5. Diagnosis 6. Treatment 7. Individual species Introduction Genus Mycobacterium
More informationPreliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease
[ Original Research Chest Infections ] Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease Julie V. Philley, MD ; Richard J. Wallace Jr, MD,
More informationClinical Management : DR-TB
Clinical Management : DR-TB Charoen Chuchottaworn MD., Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH. Tuberculosis Classification Drug susceptible TB
More informationSENSITITRE. Broth Microdilution (MIC) Method:
SENSITITRE Broth Microdilution (MIC) Method: For Rapidly Growing Mycobacteria (RGM), Slowly Growing Nontuberculosis Mycobacteria, Nocardia and other Aerobic Actinomycetes For Research Use Only For full
More informationMultidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
More informationTreatment of Multidrug-resistant Tuberculosis (MDR-TB)
Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 2006 2008 2011 2013 2014 2016 2019 Charles L. Daley, MD National Jewish Health University of Colorado Disclosures Research grant Insmed: Phase II
More informationMulti-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationChallenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
More information2/20/18
1 www.uthealth.org/microbiology 2/20/18 INTRODUCTION. Susceptibility testing, identification by DNA gene sequencing and DNA fingerprinting of the rapidly growing mycobacteria and other nontuberculous mycobacteria
More informationZyvox. Zyvox (linezolid) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.20 Subject: Zyvox Page: 1 of 7 Last Review Date: March 18, 2016 Zyvox Description Zyvox (linezolid)
More informationTreatment of Drug Resistant TB
Treatment of Drug Resistant TB Diana M. Nilsen RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Objectives Definition of other drug resistant (ODR), multiple drug resistant
More informationThe New England Journal of Medicine THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY
THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY KEMAL TAHAOĞLU, M.D., TÜLAY TÖRÜN, M.D., TÜLIN SEVIM, M.D., GÜLIZ ATAÇ, M.D., ALTAN KIR, M.D., LEVENT KARASULU, M.D., IPEK ÖZMEN, M.D., AND NILÜFER
More informationSignificant difference in drug susceptibility distribution between Mycobacterium avium
JCM Accepts, published online ahead of print on 1 October 2014 J. Clin. Microbiol. doi:10.1128/jcm.02127-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Significant difference
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Drug Resistant TB Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received research funding from
More informationManagement of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
More informationMDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX
MDR/XDR TB Barbara Seaworth, MD, FIDSA, FACP October 27, 2017 TB Intensive October 24 27, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Barbara Seaworth, MD, FIDSA, FACP, has the following disclosures
More informationTB New Drugs, Shorter Courses
TB New Drugs, Shorter Courses Brian Chong John Hunter Hospital, Newcastle NSW Talk supervisor: Chris Coulter Disclosures Unfortunately none 1 Current Situation In 2013, Australia had: 1,263 notified TB
More informationSubacute Adenitis. Ann M. Loeffler, MD
Subacute Adenitis Ann M. Loeffler, MD Lymphadenitis Swelling and hyperplasia of sinusoidal lining cells Infiltration of leukocytes +/- abscess formation Granulomatous or non-granulomatous Pyogenic adenitis
More informationMDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationTreatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos
Treatment of MDR/XDR-TB Short course chemotherapy for MDR-TB: practical issues CHIANG Chen-Yuan MD, MPH, DrPhilos Treatment strategies for MDR-TB Standardized treatment: drug resistance survey data from
More informationCase Report Atypical Mycobacterial Infection after Abdominoplasty Overseas: A Case Report and Literature Review
Case Reports in Infectious Diseases Volume 2016, Article ID 3642567, 4 pages http://dx.doi.org/10.1155/2016/3642567 Case Report Atypical Mycobacterial Infection after Abdominoplasty Overseas: A Case Report
More informationOriginal Article In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents
Int J Clin Exp Med 2015;8(9):15423-15431 www.ijcem.com /ISSN:1940-5901/IJCEM0009773 Original Article In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial
More informationTB Grand Rounds. MDR-TB: Management of Adverse Drug Reactions. Reynard J. McDonald, M.D. September 18, Patient History
TB Grand Rounds MDR-TB: Management of Adverse Drug Reactions Reynard J. McDonald, M.D. September 18, 2007 Patient History This 30 y/o H/M was born in Ecuador and immigrated to the US in 2001 On 11-22-05
More informationNew drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick Phillips Patrick.Phillips@ucsf.edu @PPJPhillips Outline Overview of regimen development strategies 1-3 year horizon: Ongoing phase
More informationTB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationThree Cases of Postoperative Septic Arthritis Caused by Mycobacterium. conceptionense in Shoulder Joints of Immunocompetent Patients
JCM Accepts, published online ahead of print on 3 January 2014 J. Clin. Microbiol. doi:10.1128/jcm.02652-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Three Cases of Postoperative
More informationStrategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
More informationMDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union Why to diagnose MDR-TB? Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56)
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 MDR/XDR TB Barbara J. Seaworth, MD October 16, 2013 Barbara J. Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial
More informationMDR TB AND CASE STUDIES
MDR TB AND CASE STUDIES Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Seattle, CITC Clinical Intensive June 15, 2018 Slide
More informationTOPICS. Continuing Education April 2014 Volume 16 Number 2. Journal of. Inside This Issue. Official publication of the American Medical Technologists
Journal of TOPICS & ISSUES Official publication of the American Medical Technologists Continuing Education April 2014 Volume 16 Number 2 Inside This Issue Back to the Future with Urinalysis: Part 2 A Confusing,
More informationAntimicrobial Susceptibility Summary 2017
Antimicrobial Susceptibility Summary 2017 Clinical Microbiology Department of Pathology & Laboratory Medicine Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory
More informationBacterial whole genome sequencing in clinical microbiology, infection control and public health. Julian Parkhill. FIS, Birmingham, November 2013
Bacterial whole genome sequencing in clinical microbiology, infection control and public health Julian Parkhill FIS, Birmingham, November 2013 Falling costs of genomics 2003 Cost/genome Throughput 60,000
More informationMultidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool)
Multidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool) DOTS + and LTBI New drugs for TB and the challenge of resistance talk plan 1. Epidemiology 2. Treatment 3. The MDRTB
More informationDr Sharanjit Dhoot. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Sharanjit Dhoot Chelsea and Westminster Hospital, London 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationTHE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION
1 THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION Dr. Norbert Ndjeka MD, DHSM (Wits), MMed(Fam Med) (MED), Dip HIV Man (SA) Director Drug-Resistant TB, TB and HIV National Department of Health
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationResearch Article Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China
BioMed Research International Volume 2015, Article ID 419392, 8 pages http://dx.doi.org/10.1155/2015/419392 Research Article Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria
More informationEAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia
EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia Background The Expert Advisory Group on Antimicrobial Resistance of the NH&MRC provides advice to Australian governments and
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationPractical. Walk through New Survival Guide
Many faces of TB: Drug resistant it ttbs Survival lgid Guide v3 P B L Ch G Sh t L T P. Barry, L. Chen, G. Schecter, L. True Curry International TB Center/CTCA April 20, 2016 Real case Practical Walk through
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationUniversity of Groningen. Tuberculosis and its sequelae Akkerman, Onno
University of Groningen Tuberculosis and its sequelae Akkerman, Onno IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas May 6 9, 2014 MDR/XDR TB Barbara Seaworth, MD May 9, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial relationships
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationWhat is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.
Pneumonia What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa www.netmedicine.com/xray/xr.htm Definition acute infectious disease, etiology usually
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More informationIdentification of Cutaneous Mycobacterium massiliense Infections Associated with Repeated Surgical Procedures
Ann Dermatol Vol. 22, No. 1, 2010 DOI: 10.5021/ad.2010.22.1.114 CASE REPORT Identification of Cutaneous Mycobacterium massiliense Infections Associated with Repeated Surgical Procedures Ah Young Cho, M.D.,
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationMicrobiology : antimicrobial drugs. Sheet 11. Ali abualhija
Microbiology : antimicrobial drugs Sheet 11 Ali abualhija return to our topic antimicrobial drugs, we have finished major group of antimicrobial drugs which associated with inhibition of protein synthesis
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationEffects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB)
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB) Session: Fanning the Flames of HIV and TB Cointeraction SA AIDS Conference-Durban ICC 13-15 June 2017
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationReceived 8 May 1996/Returned for modification 8 July 1996/Accepted 23 August 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1996, p. 2483 2487 Vol. 40, No. 11 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Spectrum of Activity of Levofloxacin against Nontuberculous
More informationCase 1 and Case 2. Case 1 3/23/2016
Case 1 and Deidra D. Parrish, MD, MPH&TM Nashville Metro Public Health Dept TB Symposium March 30, 2016 Case 1 27 yo Indian woman came to the US to join her husband three months prior to clinic visit.
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationBRUCELLOSIS BRUCELLOSIS. CPMP/4048/01, rev. 3 1/7 EMEA 2002
BRUCELLOSIS CPMP/4048/01, rev. 3 1/7 General points on treatment Four species are pathogenic to man: B. melitenis (acquired from goats), B. suis (pigs), B. abortus (cattle) and B. canis (dogs). The bacteria
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More information/journal.pone Public Library of Science. Version of Record
Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection Rose, S. J., Neville, M. E., Gupta, R., Bermudez,
More informationAntimicrobial Stewardship 101
Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationMDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2
1 MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2 1 India has the highest TB burden in the world 3 4 2 5 M. tuberculosis Resistance
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationDrug Resistant Tuberculosis:
Drug Resistant Tuberculosis: Pearls and other Considerations John W. Wilson, MD Associate Professor of Medicine Division of Infectious Diseases Mayo Clinic, Rochester MN Mayo Clinic Center for Tuberculosis
More informationAntimicrobial Resistance & Wound Infections. Li Yang Hsu 8 th April 2015
Antimicrobial Resistance & Wound Infections Li Yang Hsu 8 th April 2015 Potential Conflicts of Interest Research Funding: Pfizer Singapore AstraZeneca Janssen-Cilag Merck, Sharpe & Dohme Advisory Board:
More informationAMR Industry Alliance Antibiotic Discharge Targets
AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationXDR TB: The Laboratory s Dilemma vs The Clinician s Dilemma
XD TB: The Laboratory s Dilemma vs The Clinician s Dilemma Barbara J. Seaworth, MD, FIDSA, FACP, Heartland National TB Center, San Antonio, TX Kenneth Jost, Jr., M(ASCP) Laboratory Services Section, Texas
More informationLinezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Eur Respir J 2012; 39: 956 962 DOI: 10.1183/09031936.00076811 CopyrightßERS 2012 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India R.
More informationMycobacterium fortuitum as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature
Jiang et al. BMC Nephrology 2012, 13:35 CASE REPORT Open Access Mycobacterium fortuitum as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature Simon H Jiang
More informationNontuberculous mycobacteria in captive and pet reptiles
Nontuberculous mycobacteria in captive and pet reptiles Irena Reil, Silvio Špičić, Gordan Kompes, Sanja Duvnjak, Maja Zdelar-Tuk, Dora Stojević, Željko Cvetnić Croatian Veterinary Institute, Zagreb, Croatia
More informationPractical application of antibiotic use data. Uga Dumpis MD PhD Pauls Stradins Clinical University Hospital University of Latvia
Practical application of antibiotic use data Uga Dumpis MD PhD Pauls Stradins Clinical University Hospital University of Latvia No conflict of interest Questions for the ACASEM Survey Question 1. Antimicrobial
More informationLevofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report
46 Case Report Levofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report CT Hapuarachchi 1, GK Karunaratne 2, NR de Silva 3,
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationBRUCELLOSIS. Morning report 7/11/05 Andy Bomback
BRUCELLOSIS Morning report 7/11/05 Andy Bomback Also called undulant, Mediterranean, or Mata fever, brucellosis is an acute and chronic infection of the reticuloendothelial system gram negative facultative
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationInfectious Disease Update 2017
Infectious Disease Update 2017 Greg Moran, MD, FACEP, FIDSA Professor of Clinical Emergency Medicine Geffen School of Medicine at UCLA Dept. of Emergency Medicine and Division of Infectious Diseases Olive
More informationEradiaction of Resistant Organisms:
Eradiaction of Resistant Organisms: Can we do it and does it help? Noah Lechtzin, MD; MHS Director, Adult CF Program Outline Evidence resistant organisms are bad MRSA, B cepacia, Pseudomonas, Fungal infections
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More information